SUPRITH BADARINATH, MD

BIOGRAPHY

Dr. Suprith Badarinath is board certified in both medical oncology and hematology, and practices at our Riverside location.  He began practicing medicine in 2000, when he joined CSNF.  Born in New York, Dr. Badarinath grew up in central New Jersey and enjoys traveling, spending time with family, and photography.

Dr. Badarinath joined Cancer Specialists of North Florida in order to work in community oncology rather than academics, because he did not want to restrict his practice to one specific cancer. By working in the community, he says he is able to work with the full depth and breadth of cancer patients.  The most important way to help patients, he says, is to pay attention to the details that help get people through the day.

Working with the clinical trials offered at Cancer Specialists of North Florida is an important way Dr. Badarinath combines his master’s degree in clinical research with his desire to treat patients.  Although we have made substantial advances in the field, we still have a long way to go to improve outcomes in oncology.  It is only through active clinical trials that we can take the next steps to improve the lives of people diagnosed with cancer.  “It is through these constant steps forward that we will truly be able to make progress in cancer care,” he says.

Dr. Badarinath most enjoys the teamwork at CSNF.  He likes the spirit that everyone can work together to achieve the same goal.

Curriculum Vitae

BOARD CERTIFICATIONS

Hematology
Medical Oncology

PROFESSIONAL ASSOCIATIONS

American College of Physicians
American Society of Clinical Oncology

FELLOWSHIP

Emory University
Hematology/Oncology

RESIDENCY

Emory University

EDUCATION

Emory University
Master of Science in Clinical Research
Jefferson Medical College
Doctor of Medicine
Penn State University
Bachelor of Sciences

RESEARCH (Principal Investigator Responsibilities)

NCT00364611
A Pilot, Phase II, Multicenter, Open-Label, Prospective Evaluation of Docetaxel and Bevacizumab ± Trastuzumab in the First-Line Treatment of Patients with Metastatic Breast Cancer, Phase: II, Interventional
NCT00365365
A Phase IIb, Randomized, Multicenter, Noncomparative Pilot Study of the Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab ± Trastuzumab for the Adjuvant Treatment of Patients With Node-Positive & High-Risk Node-Negative Breast Cancer, Phase: II, Interventional
NCT00148421
A Study of Darbepoetin Alfa Administered Once Every 2 Weeks (Q2W) Compared With Epoetin Alfa Administered Once Every Week (QW) for the Treatment of Anemia in Subjects With Non-myeloid Malignancies Receiving Multicycle Chemotherapy, Phase: III, Interventional
NCT01546571
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence, Phase: III, Interventional
NCT02142218
Expanded Access Program with Nivolumab for Subjects with Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Systemic Treatment Containing an Anti CTLA-4 Monoclonal Antibody (Checkmate 168: CHECKpoint Pathway for nivoluMAb Clinical Trial Evaluation 168), Phase: III, Non-Interventional
NCT02780089
A US Multi-Site Observational Study in Patients with Unresectable And Metastatic Melanoma: The OPTIMIzE Study, Non-Interventional
NCT01077154
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 3 Study of Denosumab as Adjuvant Treatment for Women with Early-Stage Breast Cancer at High Risk of Recurrence (D-CARE), Phase: III, Interventional
NCT01610284
A Phase III Randomized, Double Blind Placebo Controlled Study of BKM120 with Fulvestrant, in Postmenopausal Women with Hormone Receptor-positive HER2-negative Locally Advanced or Metastatic Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment, Phase: III, Interventional
NCT00055419
A Phase II Study of Cetuximab in Patients Who Have Stage IV Colorectal Cancer, Phase: II, Interventional
NCT00056459
A Randomized, Double-blind, Placebo-controlled, Phase Lll Study in Patients With Metastatic Adenocarcinoma of the Colon or Rectum Who Are Receiving First-line Chemotherapy With Oxaliplatin/5-fluorouracil/Leucovorin With PTK787 or Placebo, Phase: III, Interventional
NCT01252628
Phase 1/2 Study of PX-866 and Cetuximab, Phase: I / II, Interventional
NCT01374425
MAVERICC (Marker Evaluation for Avastin Research in CRC): A Randomized Phase II Study of Bevacizumab+mFOLFOX6 Vs. Bevacizumab+FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer, Phase: II, Interventional
NCT02788279
A Phase III, Open-Label, Multicenter, Three-Arm, Randomized Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy vs. Regorafenib in Patients With Previously Treated Unresectable Locally Advanced or Metastatic Colorectal Adenocarcinoma, Phase: III, Interventional
NCT00388206
An Observational Study of Avastin (Bevacizumab) in Combination with Chemotherapy for Treatment of Metastatic or Locally Advanced and Unresectable Colorectal Cancer and Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Excluding Predominant Squamous Cell Histology), Non-Interventional
NCT00777309
A Randomized Phase 2 Study of Erlotinib Plus ARQ 197 Versus Erlotinib Plus Placebo in Previously Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC), Phase: II, Interventional
NCT00284154
A Phase II Trial of VInflunine in the Treatment of Patients with Relapsed Extensive Small Cell Lung Cancer, Phase: II, Interventional
NCT01479244
PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expressions with NeuVax™Treatment, Phase: III, Interventional
NCT01254630
A Phase III Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Efficacy of V212 in Adult Patients with Solid Tumor or Hematologic Malignancy, Phase: III, Interventional
NCT02159365
A Phase 2 Single Arm Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination with Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients, Phase: II, Interventional
NCT02186249
Expanded Access Program with Nivolumab (BMS-936558) in Combination with Ipilimumab (Yervoy®) in Subjects with Unresectable or Metastatic Melanoma, Non-Interventional
NCT01597908
A Phase III, Randomised, Open-label Study Comparing the Combination of the BRAF Inhibitor, Dabrafenib and the MEK Inhibitor, Trametinib to the BRAF Inhibitor Vemurafenib in Subjects with Unresectable (Stage IIIc) or Metastatic (Stage IV) BRAF V600E/K Mutation Positive Cutaneous Melanoma, Phase: III, Interventional
NCT01511913
A Multi-National, Prospective, Observational Study in Patients with Unresectable or Metastatic Melanoma, Non-Interventional
NCT01027598
A Randomized Phase II Double-Blind Trial of Erlotinib and Pazopanib, or Erlotinib and Placebo in Patients with Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC), Phase: II, Interventional
NCT01168973
A Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer Following Disease Progression after One Prior Platinum-Based Therapy, Phase: III, Interventional

PUBLICATIONS

Journal of Clinical Oncology
"Cetuximab Plus FOLFOX for Colorectal Cancer (EXPLORE): Preliminary Safety Analysis of a Randomized Phase III Trial"
2005 ASCO Annual Meeting Proceedings
"Erbitux (Cetuximab) Plus FOLFOX for Colorectal Cancer (EXPLORE): Preliminary Efficacy Analysis of a Randomized Phase III Trial"
Journal of Clinical Oncology
“Risk Factors for Gastrointestinal Perforations in Patients with Metastatic Colorectal Cancer receiving Bevacizumab plus Chemotherapy”,
2006 ASCO Annual Meeting Proceedings
“Efficacy of Bevacizumab plus Chemotherapy as First-Line Treatment of Patients with Metastatic Colorectal Cancer: Updated Results from a Large Observational Registry in the US (BRITE)”,
2006 ASCO Annual Meeting Proceedings
“Safety of Bevacizumab plus Chemotherapy as First-Line Treatment of Patients with Metastatic Colorectal Cancer: Updated Results from a Large Observation Registry in the US (BRITE)”,
2006 ASCO Annual Meeting Proceedings
“R.V. Boccia, Cetuximab + FOLFOX6 as First-Line Therapy for Metastatic Colorectal Cancer (An International Oncology Network study, I-03-002)”,
Clinical Colorectal Cancer
“A Phase II Trial of FOLFOX6 and Cetuximab in the First-line Treatment of Patients With Metastatic Colorectal Cancer”.
42nd Annual Meeting of the America Society of Clinical Oncology
“Safety of Bevacizumab plus chemotherapy as 1st-line treatment of patients with metastatic colorectal cancer: Updated Results From a Large Observational Study in the U.S. (BRiTE)”
42nd Annual Meeting of the America Society of Clinical Oncology
"Efficacy of Bevacizumab plus chemotherapy as 1st-line treatment of patients with metastatic colorectal cancer: Updated results from a large observational study in the U.S. (BRiTE)"
42nd Annual Meeting of the America Society of Clinical Oncology
"Risk factors for gastrointestinal perforations in patients with metastatic colorectal cancer receiving Bevacizumab plus chemotherapy."
2007 Gastrointestinal Cancers Symposium
"Management of hypertension in patients with metastatic colorectal cancer treated with Bevacizumab plus chemotherapy."
43nd Annual Meeting of the American Society of Clinical Oncology
“A multicenter study of 3 docetaxel regimens with Bevacizumab as adjuvant therapy for breast cancer (BC): Preliminary results.”
Gastrointestinal Cancer Symposium
. “Survival of patients with metastatic colorectal cancer treated with Bevacizumab in combination with chemotherapy: Results from the BRiTE registry.”